AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases

Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technology

WHITE PLAINS, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc. today announced the publication of two new peer-reviewed studies that expand the clinical evidence base for AlloFlo™ Uveo, bringing the total number of peer-reviewed publications to seven. Together with nearly 3,000 procedures performed in the United States, the findings highlight both the scientific and real-world momentum behind surgical uveoscleral outflow enhancement in glaucoma care.

The first paper, published in Clinical Ophthalmology, presents Level I clinical evidence and is the largest systematic review and meta-analysis of ab-interno uveoscleral outflow enhancement covering more than a century of surgical experience and over 4,000 eyes across 40 cyclodialysis studies.

Link to publication: OPTH_A_538438 2859..2870

According to lead author Dr. Robert Stamper, Professor at UCSF, “The analysis confirms cyclodialysis as an effective procedure for enhancing uveoscleral outflow, with modern ab-interno approaches showing improved intraocular pressure (IOP)-lowering efficacy, safety, and durability.”

Building on this foundation, a second paper reports one-year prospective clinical results in 51 eyes with uncontrolled primary open-angle glaucoma treated with bio-reinforced cyclodialysis using AlloFlo™ Uveo.

Link to publication: 10.1177_25158414251362010.pdf

Patients experienced a statistically significant and sustained reduction in IOP — from 25.7 mmHg at baseline to 15.4 mmHg at 12 months, representing a 40% relative decrease — along with a 42% reduction in the use of IOP-lowering medications.

With these additions, the body of peer-reviewed evidence generated from the CREST study, continues to grow. Iantrek is preparing for a formal commercial launch of AlloFlo™ Uveo at the American Academy of Ophthalmology (AAO) Annual Meeting later this year.

“The growing body of peer-reviewed evidence represents an important step in glaucoma care,” said Dr. Arsham Sheybani. “Patients should have access to a full range of surgical options, including approaches that engage the uveoscleral pathway for appropriate candidates. Supported by real-world evidence data from the CREST Study, AlloFlo™ Uveo appears to be a valuable addition to our surgical armamentarium.”

About Iantrek
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The company’s portfolio includes AlloSert™ Uveo, AlloFlo™ Uveo, and C.Rex™— bio-interventional and micro-interventional solutions for the management of glaucoma. For more information, visit iantrekmed.com.

Media Contact
Amy Phillips
MediaInquiries@iantrekmed.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.